HRP20200601T1 - Inhibiranje ionskog kanala za prolazni receptorski potencijal a1 - Google Patents

Inhibiranje ionskog kanala za prolazni receptorski potencijal a1 Download PDF

Info

Publication number
HRP20200601T1
HRP20200601T1 HRP20200601TT HRP20200601T HRP20200601T1 HR P20200601 T1 HRP20200601 T1 HR P20200601T1 HR P20200601T T HRP20200601T T HR P20200601TT HR P20200601 T HRP20200601 T HR P20200601T HR P20200601 T1 HRP20200601 T1 HR P20200601T1
Authority
HR
Croatia
Prior art keywords
image
compound according
alkyl
methyl
cyano
Prior art date
Application number
HRP20200601TT
Other languages
English (en)
Inventor
Bertand L. Chenard
Xinyuan Wu
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20200601T1 publication Critical patent/HRP20200601T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Electrotherapy Devices (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (18)

1. Spoj Formule (I): [image] , ili njegova farmaceutski prihvatljiva sol, naznačen time što: R1 je hidroksipropil, hidroksietil, ketopentil, hidroksimetil, piridinilmetil, oksazolilmetil, metilizoksazolilmetil, oksetanilmetil, oksadiazolilmetil, metiloksadiazolilmetil, metoksietil, hidroksimetoksipropil, metoksiketopropil, ketometilbutil, ketopropil, ketobutil, acetamido, cijanometil, metilacetamido, trifluoretil, trifluorpropil ili butinil; R2 je H ili C1-C6 alkil; R3 je fenil, piridil, pirimidinil, pirazinil ili tiazolil, od kojih je svaki supstituiran s (R4)1-2; R4 je neovisno H, C1-C3 alkil, C1-C3 alkoksi, C1-C3 halogenalkil, -N(R8)2, 3- do 8-eročlani cikloalkil, aril, heterociklil, heteroaril, cijano ili halogen, ili dva R4 zajedno s atomima na koje su vezani mogu tvoriti izborno supstituirani 3- do 7-eročlani prsten, od kojih svaki može biti supstituiran s (R5)1-3; R5 je neovisno H, C3-C10 heterociklil, C1-C3 alkil, C1-C3 alkoksi, -C1-C6 alkil-O-C0-C6 alkil, -C0-C6 alkil-O-C1-C6 alkil, -N(C1-C3 alkil)2, C1-C6 halogenalkil, -C1-C3 alkil-N(R8)2, heterociklilalkil, halogen, cijano ili keto, od kojih svaki može biti supstituiran s (R7)1-3; R6 je H ili C1-C6 alkil; R7 je neovisno H, C1-C6 alkil, C2-C6 alkenil, C2-C6 alkinil, C1-C6 alkoksi, C1-C6 halogenalkil, hidroksi, aril, heteroaril, heterociklil, arilalkil, ariloksi, heteroariloksi, arilalkoksi, heteroarilalkoksi, heterarilalkil, halogenalkil, keto, cijano ili halogen, ili dva R7 zajedno s atomima na koje su vezani mogu tvoriti izborno supstituirani 3- do 7-eročlani prsten; i R8 je H, C1-C6 alkil ili C1-C6 halogenalkil.
2. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je R1 [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] .
3. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što a) R2 je metil; ili b) R2 je H.
4. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je R3 [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] .
5. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je R4 neovisno H, metil, etil, propil, -N(R8)2, fenil, halogen, cijano, halogenalkil, metoksi, piridinil, pirimidinil, oksadiazolil, piperidinil, azetidinil, pirazinil, azabicikloheksil, piperazinil ili pirolidinil, od kojih je svaki supstituiran s (R5)1-2.
6. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je R4 neovisno H, metil, etil, propil, cijano, metoksi, klor, fluor, brom, -CF3, -CF2, [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] .
7. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je R5 neovisno H, pirolidinil, trifluormetil, trifluoretil, halogen, metil, izopropil, cijano, propil, etil, azabicikloheksil, difluorazabicikloheksil, keto, metoksi, metoksietil, dialkilamino ili etoksi, od kojih svaki može biti supstituiran s (R6)1-3; gdje R5 može biti neovisno H, -CF3, cijanometil, brom, klor, fluor, metil, etil, izopropil, cijano, keto, [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] .
8. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što a) R6 je H; ili b) R6 je metil.
9. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je R8 H, metil, etil ili CF3.
10. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je R1 [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] ; R2 je H ili metil; R3 je [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] ; R4 je neovisno H, metil, etil, propil, cijano, metoksi, klor, fluor, brom, -CF3, -CF2, [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] ; R5 je neovisno H, -CF3, cijanometil, brom, klor, fluor, metil, etil, izopropil, cijano, keto, [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] ; R6 je H ili metil; i R8 je H, metil, etil ili CF3.
11. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se spoj bira iz skupine koju čine: [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] , [image] .
12. Spoj, naznačen time što ga se bira iz skupine koju čine: [image] , [image] , [image] , [image] , [image] , [image] , [image] ili [image] .
13. Spoj u skladu s patentnim zahtjevom 11, naznačen time što je: [image] .
14. Spoj u skladu s patentnim zahtjevom 11, naznačen time što je: [image] .
15. Spoj u skladu s patentnim zahtjevom 11, naznačen time što je: [image] .
16. Farmaceutski pripravak, naznačen time što sadrži najmanje jedan spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegovu farmaceutski prihvatljivu sol, u smjesi s farmaceutski prihvatljivom pomoćnom tvari, razrjeđivačem ili nosačem.
17. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen upotrebi kao medikament.
18. Spoj u skladu s bilo kojim od prethodnih patentnih zahtjeva, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja posredovanog s TRPA1 kod subjekta, gdje se poremećaj posredovan s TRPA1 bira iz skupine koju čine: bol, upalna bolest, dermatološki poremećaj ili respiratorno stanje.
HRP20200601TT 2014-09-19 2020-04-16 Inhibiranje ionskog kanala za prolazni receptorski potencijal a1 HRP20200601T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052678P 2014-09-19 2014-09-19
EP15774806.2A EP3193880B1 (en) 2014-09-19 2015-09-18 Inhibiting the transient receptor potential a1 ion channel
PCT/US2015/051063 WO2016044792A1 (en) 2014-09-19 2015-09-18 Inhibiting the transient receptor potential a1 ion channel

Publications (1)

Publication Number Publication Date
HRP20200601T1 true HRP20200601T1 (hr) 2020-07-10

Family

ID=54249631

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200601TT HRP20200601T1 (hr) 2014-09-19 2020-04-16 Inhibiranje ionskog kanala za prolazni receptorski potencijal a1

Country Status (18)

Country Link
US (2) US10221177B2 (hr)
EP (1) EP3193880B1 (hr)
JP (4) JP6571173B2 (hr)
CN (1) CN106715430B (hr)
AU (1) AU2015317332B2 (hr)
CA (1) CA2961412C (hr)
CY (1) CY1123059T1 (hr)
DK (1) DK3193880T3 (hr)
ES (1) ES2788395T3 (hr)
HR (1) HRP20200601T1 (hr)
HU (1) HUE049253T2 (hr)
LT (1) LT3193880T (hr)
PL (1) PL3193880T3 (hr)
PT (1) PT3193880T (hr)
RS (1) RS60192B1 (hr)
SI (1) SI3193880T1 (hr)
TW (1) TWI704149B (hr)
WO (1) WO2016044792A1 (hr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
PL3193880T3 (pl) * 2014-09-19 2020-09-07 Eli Lilly And Company Hamowanie kanału jonowego receptora przejściowego potencjału A1
US10278973B2 (en) 2015-05-20 2019-05-07 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and use thereof
TWI690529B (zh) * 2015-05-20 2020-04-11 大陸商廣東衆生睿創生物科技有限公司 羥基嘌呤類化合物及其應用
TWI690526B (zh) * 2015-05-20 2020-04-11 大陸商廣東衆生睿創生物科技有限公司 羥基嘌呤類化合物及其應用
CN107614501B (zh) 2015-05-20 2020-01-14 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
WO2018109155A1 (en) * 2016-12-16 2018-06-21 Galderma Research & Development Trpa1 antagonists for use in the treatment of atopic dermatitis
US11161849B2 (en) * 2018-01-31 2021-11-02 Eli Lilly And Company Inhibiting the transient receptor potential al ion channel
MX2021014441A (es) 2019-05-31 2022-01-06 Ikena Oncology Inc Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
US10582716B1 (en) 2019-06-14 2020-03-10 Lennham Pharmaceuticals, Inc. Deuterated caffeine and uses thereof
FR3114235A1 (fr) 2020-09-18 2022-03-25 Université Grenoble Alpes Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer
IT202100015098A1 (it) 2021-06-09 2022-12-09 Flonext S R L Composto antagonista del canale trpa1 per uso in patologie degenerative della retina
KR20230027841A (ko) 2021-08-20 2023-02-28 주식회사 엘지에너지솔루션 충방전 전력 제어 장치, 에너지 저장 시스템 및 에너지 저장 시스템의 동작 방법
WO2023133502A1 (en) * 2022-01-07 2023-07-13 The Johns Hopkins University Treatment and prevention of trigeminal neuralgia
CN114671876B (zh) * 2022-04-27 2023-10-03 成都施贝康生物医药科技有限公司 新型茶碱类化合物、异构体或盐及其制备方法和用途
CN116655635B (zh) * 2023-05-19 2024-01-26 济南爱思医药科技有限公司 黑茶茶碱衍生物及在制备药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101384261B (zh) 2005-12-22 2011-12-07 海德拉生物科学公司 治疗疼痛的组合物
AU2008268463B2 (en) * 2007-06-22 2015-03-05 Eli Lilly And Company Methods and compositions for treating disorders
WO2009140517A1 (en) * 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
US20120046305A1 (en) 2008-09-24 2012-02-23 Moran Magdalene M Methods and compositions for treating respiratory disorders
WO2013023102A1 (en) 2011-08-09 2013-02-14 Hydra Biosciences, Inc. Inhibiting transient receptor potential ion channel trpa1
TW201441225A (zh) 2013-01-18 2014-11-01 Cubist Pharm Inc 瞬時受體電位ａ１離子通道之抑制
GB201309333D0 (en) * 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
TWI676626B (zh) 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
PL3193880T3 (pl) * 2014-09-19 2020-09-07 Eli Lilly And Company Hamowanie kanału jonowego receptora przejściowego potencjału A1

Also Published As

Publication number Publication date
WO2016044792A1 (en) 2016-03-24
TW201625619A (zh) 2016-07-16
JP2021120403A (ja) 2021-08-19
RS60192B1 (sr) 2020-06-30
SI3193880T1 (sl) 2020-06-30
PL3193880T3 (pl) 2020-09-07
TWI704149B (zh) 2020-09-11
EP3193880B1 (en) 2020-03-25
CA2961412C (en) 2024-01-16
AU2015317332A1 (en) 2017-03-16
JP7181967B2 (ja) 2022-12-01
ES2788395T3 (es) 2020-10-21
JP6571173B2 (ja) 2019-09-04
JP2019206577A (ja) 2019-12-05
EP3193880A1 (en) 2017-07-26
JP2017528490A (ja) 2017-09-28
HUE049253T2 (hu) 2020-09-28
DK3193880T3 (da) 2020-06-02
CY1123059T1 (el) 2021-10-29
CN106715430B (zh) 2019-09-17
PT3193880T (pt) 2020-06-19
JP2023015338A (ja) 2023-01-31
LT3193880T (lt) 2020-05-11
US20190330212A1 (en) 2019-10-31
US20170275285A1 (en) 2017-09-28
AU2015317332B2 (en) 2019-07-18
CA2961412A1 (en) 2016-03-24
CN106715430A (zh) 2017-05-24
US10221177B2 (en) 2019-03-05
US10519158B2 (en) 2019-12-31

Similar Documents

Publication Publication Date Title
HRP20200601T1 (hr) Inhibiranje ionskog kanala za prolazni receptorski potencijal a1
HRP20210693T1 (hr) Inhibitori beta-laktamaze
HRP20191268T1 (hr) Derivati tieno[2,3-c]pirol-4-ona kao inhibitori erk
HRP20210879T1 (hr) Inhibitori beta-laktamaze
JP2016506960A5 (hr)
HRP20200538T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
HRP20180081T1 (hr) Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze
HRP20210344T1 (hr) Pripravci i postupci liječenja poremećaja cns
HRP20200648T1 (hr) Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
JP2019081762A5 (hr)
JP2016512520A5 (hr)
JP2016512834A5 (hr)
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
HRP20161541T1 (hr) Fuzionirani biciklični oksazolidinon kao inhibitor cetp
HRP20221294T1 (hr) Neuroaktivni steroidi, njihovi pripravci i uporabe
JP2016523955A5 (hr)
JP2018529739A5 (hr)
SI2935307T1 (en) Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures
HRP20100677T1 (hr) IMIDAZO[1,2-a]PIRIDINSKI SPOJEVI KAO INHIBITORI VEGF-R2
HRP20191826T4 (hr) Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta
JP2016515582A5 (hr)
JP2014503525A5 (hr)
RU2013138834A (ru) N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2
HRP20120202T1 (hr) AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET
JP2012111770A5 (hr)